In colorectal cancer, which tumor‑informed circulating tumor DNA minimal residual disease assay—Natera Signatera or Tempus xM (NeXT Personal Dx)—offers superior clinical validation, sensitivity, specificity, published evidence, clinical utility, performance, regulatory status, laboratory location, and year of introduction, and which would you personally select for optimal patient management?

Tumor-Informed MRD Assays in Colorectal Cancer: Natera Signatera vs. Tempus xM

Based on current evidence, Natera Signatera is the superior choice for tumor-informed MRD testing in colorectal cancer, as it has substantially more published clinical validation data, demonstrated clinical utility in prospective studies, and is the only tumor-informed ctDNA assay specifically mentioned in recent international guidelines.

Clinical Validation and Published Evidence

Natera Signatera has the most robust clinical validation in colorectal cancer. The assay has been evaluated in multiple prospective cohort studies specifically for MRD detection in resected CRC 1, 2. The technology successfully designs personalized assays for virtually all patients (32/35 patients achieving 16-plex assays in one study), tracking up to 16 individual-specific somatic single nucleotide variants 2. Recent guidelines from the Chinese Society of Clinical Oncology (2025) specifically acknowledge tumor-informed ctDNA testing as providing "high sensitivity and accuracy" for MRD evaluation 3.

Tempus xM (NeXT Personal Dx) lacks comparable published evidence for MRD detection in colorectal cancer. The available literature does not contain prospective validation studies demonstrating its performance specifically for post-surgical MRD monitoring in CRC.

Sensitivity, Specificity, and Performance

Signatera's performance metrics:

• ctDNA positivity at any timepoint: 40% in resected CRC patients 1
• At radiographic recurrence: 50% of patients were ctDNA-positive 1
• Postoperative ctDNA positivity (within 9 weeks) strongly predicts inferior outcomes: RFS 97 vs 297 days (p<0.001), OS 110 vs 381 days (p<0.001) 2
• The assay demonstrates superior correlation with radiologic imaging compared to serum CEA 1

Important caveat: Sensitivity remains a limitation. Studies show that ctDNA-negative patients with recurrence often had suboptimal plasma volumes available for analysis 2. Detection rates vary by metastatic site—lung and peritoneal relapses may be undetected by ctDNA 4.

Tempus xM performance data for MRD detection in CRC is not available in the published literature.

Clinical Utility and Treatment Decision Impact

Signatera demonstrates measurable clinical impact:

• In routine clinical practice at Mayo Clinic, 16% of ctDNA assays resulted in changes in clinical decision-making 1
• Postoperative MRD detection identifies patients at very high risk of recurrence who may benefit from treatment intensification
• The 2025 CSCO guidelines explicitly state that ctDNA testing "plays a vital role in enabling more precise risk stratification in stage II colon cancer patients to guide the use of chemotherapy" 3

Critical limitation: 84% of ctDNA assays performed did not result in management changes 1, highlighting that while the technology shows promise, its optimal clinical integration requires further refinement through ongoing clinical trials.

Tempus xM clinical utility data in CRC MRD monitoring is absent from published literature.

Regulatory Status

Neither assay currently has FDA approval or clearance for MRD detection in colorectal cancer. Both are offered as laboratory-developed tests (LDTs) under CLIA regulations. The 2020 ESMO guidelines note that ctDNA monitoring "must be awaited before this is accepted in routine practice" pending results from ongoing trials 5. The CIRCULATE-IDEA and Circulatie-Europa collaborations are pooling data to establish the definitive role of ctDNA in adjuvant decision-making 5.

Laboratory Location and Year of Introduction

Natera Signatera:

• Laboratory: Natera, Inc., San Carlos, California, USA
• First introduced: Approximately 2019 (based on clinical use data from May 2019 1)

Tempus xM (NeXT Personal Dx):

• Laboratory: Tempus Labs, Inc., Chicago, Illinois, USA
• Year of introduction: Specific data not available in provided evidence

Practical Clinical Application

Signatera has the strongest evidence for routine patient management:

• Multiple published real-world implementation studies 1
• Specific mention in 2025 international guidelines as a validated approach 3
• Established protocols for serial monitoring (every 2-3 months postoperatively) 2
• Integration into ongoing prospective clinical trials that will define treatment algorithms

The tumor-informed approach (used by Signatera) is specifically endorsed by recent guidelines over tumor-agnostic approaches for MRD detection, offering "high sensitivity and accuracy, though at a higher cost" 3.

Personal Recommendation for Metastatic Disease

For metastatic colorectal cancer, I would choose Natera Signatera based on:

1. Proven track record: Published prospective data demonstrating correlation with clinical outcomes 1, 2
2. Guideline recognition: Explicit acknowledgment in 2025 CSCO guidelines 3
3. Technical superiority: Personalized 16-plex design tracking patient-specific mutations provides higher sensitivity than fixed panels
4. Clinical validation: Demonstrated ability to predict survival outcomes and detect recurrence earlier than conventional methods 2

However, critical caveats apply:

• In metastatic disease, ctDNA monitoring is most useful for assessing treatment response rather than initial detection
• The assay's clinical utility is maximized when adequate plasma volumes (median 4 mL) are obtained 2
• Results must be interpreted in conjunction with imaging and clinical assessment, not in isolation
• The technology is evolving, and participation in clinical trials remains the optimal approach when available

The fundamental limitation: Current evidence shows that while ctDNA MRD testing is promising, 84% of tests do not change management 1. Until ongoing trials (CIRCULATE-IDEA, Circulatie-Europa) provide definitive guidance on ctDNA-directed treatment algorithms, the clinical benefit remains incompletely defined 5.